Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Medical
- Diagnostic
- Cancer
- Device
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 383615
License Grant
The University grants the right and worldwide, non-exclusive license, with the right to grant sublicenses, in the Field to make, have made, use, sell, offer for sale, and import the Licensed Technology and to practice under the Patent Rights to the end of the term.
License Property
University is the joint owner by assignment with Carnegie Mellon University of certain Patent Rights,
The Patent Rights are titled A Method and Apparatus for Holding Cells.
Field of Use
The Field shall mean human and veterinary cellular imaging in the Cancer Diagnostics Field and the Drug Development Field.
The Cancer Diagnostics Field shall mean diagnostic assays to detem1ine therapeutic efficacy of then-available chemotherapeutics or biologics on cancer or screening assays for the detection of cancer.
The Drug Development Field shall mean research conducted to measure the effect of preclinical, clinical or commercial stage cancer agents on primary or early passage cell strains.
IPSCIO Record ID: 328125
License Grant
The University grants a worldwide, exclusive license to Licensor’s rights in the Agreement Patents, along with the right by Licensee only to grant sublicenses, to make, have made, use, have used, provide, import, have imported, offer to sell, sell and have sold Licensed Products.
License Property
Licensor is the owner of a patent application related to an in vivo quantitative screening test for anti-metastasis treatment efficacy.
The patent is titled An In Vivo Quantitative Screening Test For Anti-Metastasis Treatment Efficacy.
Field of Use
The Diagnostic Field means products and services for diagnostic use.
The Therapeutic Field means products and services for therapeutic use.
IPSCIO Record ID: 328124
License Grant
The University grants a worldwide, exclusive license to Licensor’s rights in the Agreement Patents, along with the right by Licensee only to grant sublicenses, to make, have made, use, have used, provide, import, have imported, offer to sell, sell and have sold Licensed Products.
License Property
Licensor is the owner of a patent application related to isolation, gene expression, and chemotherapeutic resistance of motile cancer cells and human invasion signature for prognosis of metastatic risk.
The patents include Isolation, Gene Expression, And Chemotherapeutic Resistance Of Motile Cancer Cells, and, Human Invasion Signature For Prognosis Of Metastatic Risk.
The intellectual property covered by the Second License Agreement are summarized as follows
1.
U.S. Patent Application No. 11/659,514 entitled “Isolation, Gene Expression, And Chemotherapeutic Resistance Of Motile Cancer Cellsâ€
2.
Canadian Patent Application No. 2,576,702 entitled “Isolation, Gene Expression, And Chemotherapeutic Resistance Of Motile Cancer Cellsâ€
3.
European Patent Application No. 05807467.5 entitled “Isolation, Gene Expression, And Chemotherapeutic Resistance Of Motile Cancer Cellsâ€
4.
U.S. Provisional Patent Application (pending) entitled “Human Invasion Signature For Prognosis Of Metastatic Riskâ€
The intellectual property covered by the Third License Agreement are summarized as follows
1.
U.S. Patent Application No. 12/998,237 (based on PCT International Patent Application No. PCT/2009/005851) entitled “An In Vivo Quantitative Screening Test For Anti-Metastasis Treatment Efficacyâ€
Field of Use
The Diagnostic Field means products and services for diagnostic use.
The Therapeutic Field means products and services for therapeutic use.
IPSCIO Record ID: 28487
License Grant
The Licensor granted the Licensee a non-exclusive license agreement for the use of the patent rights and technology as they relate to cervical and ovarian cancer.
License Property
The Company agreed to settle an arbitration proceeding instituted by anther party against the Company through the transfer to the other party of certain patents, patent applications and other intellectual property rights relating to the AcCell technology.
The AcCell product is a computer-aided automated microscopy instrument designed to help medical specialists examine and diagnose specimens of human cells.
U.S. Patent 6,535,626; 6,430,309; 6,285,498; 6,148,096; 6,151,161; 6,118,581; 6,091,842; 6,081,740; 5,999,844; 5,963,368; 5,930,732; 5,833,794; 5,690,892; 5,077,806; 5,073,857
Field of Use
Licensed Field shall mean the field of products designed, developed, tested, manufactured, distributed, marketed, approved, sold, provided, and/or used exclusively for the screening of cervical or ovarian cancer which require the incorporation of a fluorescent probe as its primary probe, or which may incorporate other fluorescent or non-fluorescent probes, and in which the assay itself (a procedure employing one or more reagents which determines the biological state of a clinical specimen comprised of cells or tissues) is primarily fluorescent.
Licensee have designed and manufactured the AcCell(TM) computer-aided automated microscopy instrument and the AcCell Savant(TM), an instrument that includes an AcCell instrument and software and which collects quantitative cellular information used in support of a diagnostic process.
Licensee is a life sciences company engaged in the design, development and commercialization of cost-effective screening systems to assist in the early detection of cancer.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
